BALTIMORE, Dec. 14,
2023 /PRNewswire/ -- Haystack Oncology, a Quest
Diagnostics (NYSE: DGX) company, has entered into a collaboration
with Rutgers Cancer Institute of New
Jersey to use Haystack Oncology's industry-leading
personalized MRD technology (Haystack MRD™) to help evaluate
therapeutic response and provide molecular insights for a
Rutgers Cancer Institute clinical trial examining
early-stage triple-negative breast cancer (TNBC) patients
undergoing treatment in the adjuvant setting with liposomal
doxorubicin and carboplatin. Rutgers Cancer Institute together with
RWJBarnabas Health is the state's only National Cancer
Institute-designated Comprehensive Cancer Center.
![Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated) Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)](https://mma.prnewswire.com/media/200883/quest_diagnostics_incorporated_logo_logo.jpg)
"We're excited to work with Rutgers Cancer Institute in their
efforts to optimize therapeutic strategies for patients with
early-stage breast cancer," said Dan
Edelstein, Vice President and General Manager of Haystack
Oncology. "With unparalleled sensitivity, Haystack MRD provides a
tool for anticipating and evaluating treatment-related benefits to
a greater depth than standard clinical and radiographic metrics,
making it well-equipped to support clinical studies such as this,
which are essential for advancing cancer care."
"Triple-negative breast cancer is a subtype of breast cancer
that is aggressive by nature with a complex
biology, therefore, the disease tends to have a worse
prognosis," said Mridula George, MD,
associate program director of Breast Medical Oncology at Rutgers
Cancer Institute and principal investigator of the study, which is
also open at select RWJBarnabas Health sites across New Jersey. "We are excited to use Haystack's
MRD technology to monitor treatment response in our clinical trial
that could help inform future studies and novel approaches that
will result in better outcomes for our patients."
About Haystack Oncology
Haystack Oncology represents
the culmination of over 20 years of technical and clinical
development in liquid biopsy technologies by cancer genomics
pioneers at Johns Hopkins School of
Medicine. The company, a wholly owned subsidiary of Quest
Diagnostics, developed Haystack MRD™, a next generation tumor
informed approach for the measurement of minimal residual disease.
Haystack MRD uses an error-corrected ctDNA technology to detect
down to one ctDNA molecule in a million. Haystack Oncology works
with biopharmaceutical companies to advance important therapeutics
to global markets, from early phase clinical development to
companion diagnostics. By detecting patients with measurable
disease for enrollment, and helping to identify early treatment
response and disease clearance as endpoints for treatment efficacy,
Haystack Oncology can accelerate and improve the efficiency of
clinical development programs. Haystack Oncology testing is CLIA
certified in the US and is available for biopharmaceutical clinical
development in laboratories located in Baltimore, Maryland, Hamburg, Germany and Helsinki, Finland. Learn more at
haystackoncology.com.
About Quest Diagnostics
Quest Diagnostics empowers
people to take action to improve health outcomes. Derived from the
world's largest database of clinical lab results, our diagnostic
insights reveal new avenues to identify and treat disease, inspire
healthy behaviors and improve health care management. Quest
annually serves one in three adult Americans and half the
physicians and hospitals in the United
States, and our nearly 50,000 employees understand that, in
the right hands and with the right context, our diagnostic insights
can inspire actions that transform lives.
www.QuestDiagnostics.com.
About Rutgers Cancer Institute of New Jersey
As New Jersey's only National Cancer
Institute-designated Comprehensive Cancer Center, Rutgers Cancer
Institute, together with RWJBarnabas Health, offers the most
advanced cancer treatment options, including bone marrow
transplantation, proton therapy, CAR T-cell therapy and complex
surgical procedures. Along with clinical trials and novel
therapeutics such as precision medicine and immunotherapy – many of
which are not widely available – patients have access to these
cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New
Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in
Newark, as well as through
RWJBarnabas Health facilities.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/haystack-oncology-and-rutgers-cancer-institute-collaborate-to-use-haystack-mrd-in-clinical-study-of-early-stage-triple-negative-breast-cancer-302015627.html
SOURCE Quest Diagnostics